On February 19, CSPC Pharmaceutical Group announced that its subsidiary CSPC Pharmaceutical Group Jushi Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jushi Bio") has reached an important agreement with Radiance Biopharma. According to the agreement, Radiance Biopharma will obtain the exclusive development and commercialization rights of Jushi Bio's independently developed SYS6005 project in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia and Canada. Jushi Bio will receive a down payment of US$15 million, a development and regulatory milestone amount of US$150 million, a sales milestone amount of US$1.075 billion, and a certain percentage of sales revenue.

SYS6005: An innovative ADC drug

SYS6005 is a monoclonal antibody-drug conjugate (ADC) independently developed by Jushi Bio. It can bind to specific receptors on the surface of tumors, enter cells through endocytosis and release toxins to kill tumor cells.

SYS6005 uses Jushi Bio's enzyme-catalyzed site-specific antibody conjugation technology. Through stable connection technology, it can effectively reduce the systemic exposure of the mitotic inhibitor MMAE, target ROR1-expressing cancer cells and release toxins, thereby reducing drug-related side effects.

According to Yaozhi data, SYS6005 was declared as a Class 1 therapeutic biologic and was approved for IND in China in December 2024, with the proposed indication being advanced tumors.

2025: A bumper year for ADC drug exports

In 2025, ADC will still be the pioneer of domestic innovative drugs going overseas. Since the beginning of the year, a number of major transactions have been concluded, including the licensing of Yingen Bio's EGFR/HER3 ADC to Avenzo, the licensing of Lepu Bio's gastrointestinal tumor ADC to Arrivent, the licensing of Innovent Biologics' DLL3 ADC to Roche, and the licensing of CSPC Pharmaceutical Group's ROR1 ADC to Radiance Biopharma.

The cooperation between CSPC and Radiance Biopharma not only paves the way for the global development and commercialization of SYS6005, but also brings considerable economic returns to CSPC. With the widespread application of ADC drugs around the world, Chinese biopharmaceutical companies are gradually occupying an important position on the international stage.

https://news.yaozh.com/archive/45025.html